| Gene name: | SIRT1 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | VSMC |
| Experiment: | SA-β-gal activity assay//Western blot//qRT-PCR |
| Description: | Senescence was evident at day 4 with an inverse correlation (p < 0.0359) (r2 = 0.2469) between SIRT1 levels and the presence of senescent cells.Furthermore, there was a significant increase in the level of cellular senescence under osteogenic conditions compared to untreated control cells (p < 0.0417), and a further increase in the numbers of SA-βgal positive cells when exposed to hyperglycaemic osteogenic conditions, compared to the osteogenic conditions (p < 0.0094).Upstream of p21, p53 mRNA was also increased in all treatments where SIRT1 is inhibited (p < 0.0232). |
| Regulatory pathway: | RUNX2 |
| R-AG-Pathway: | Downregulation |
| Official symbol(s): | RUNX2 |
| Pathway experiment: | ChIP//Western blot//qRT-PCR |
| Pathway description: | The acetylation profile of the RUNX2 promotor was measured via ChIP qPCR. RUNX2 promotor acetylation was significantly reduced in the hyperglycaemic conditions with the addition of SRT1720, suggesting a decrease in RUNX2 transcription was a direct result of SIRT1 activation . Furthermore, SRT1720 activation of SIRT1 activity resulted in a reduction in RUNX2 mRNA under osteogenic conditions, with a further significant reduction in RUNX2 expression under hyperglycaemic conditions (p < 0.0231), compared to the untreated cells. The decrease in RUNX2 mRNA expression after SIRT1 activation correlates with a decrease in RUNX2 protein expression in both osteogenic and hyperglycaemic conditions at day 4. Conversely, RUNX2 protein was increased following inhibition of SIRT1. |
Annotation:
Loading,please wait...